Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2575 in relapsed/refractory multiple myeloma
CTR20202584Phase 2Terminated
- Sponsor
- Suzhou Ascentage Pharma Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in multiple myeloma (MM), sponsored by Suzhou Ascentage Pharma Co., Ltd.. Started Dec 2020; status: terminated.
02
Drugs
lisaftoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20202584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202584.